CAPR Stock, Capricor Therapeutics Inc. Information

Los Angeles based Capricor Therapeutics, Inc. CAPR is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases. The Company has six drug candidates in stages of development which includes CAP , CAP , CSps, Exosomes, Cenderitide and CU NP. Capricor s lead product candidate, an allogeneic cardiosphere derived cell CDC product, CAP , aims to attenuate and potentially improve damage to the heart caused by a heart attack and is currently under evaluation in the Phase I/II ALLSTAR clinical trial of patients days to year after a heart attack. Ongoing research at Capricor focuses on in depth product characterization, expanded use of current products, development of next generation products, and identification of new technologies. The company was founded in and is headquartered in Beverly Hills, CA.